Articles By Wayne Koberstein, Executive Editor

CtW - Castle Creek_450x300
Companies To Watch: Castle Creek Biosciences
For Castle Creek Biosciences, there are many stakes at play in targeting rare skin, connective tissue, liver, and metabolic disorders.  Continue Reading..
  • Platforms To Pipelines: Part 2
    5/2/2022

    In part 2 of this series, we cover each company’s future plans, as well as their leaders’ observations of the platform-to-pipeline space they are effectively expanding, by joining a gathering crowd of companies now entering it.

  • Beyond Profits To Biopharma Innovation
    4/1/2022

    What if, for certain ambitious but traditionally underfunded areas needing innovation, a startup could achieve its ends without the usual for-profit incentives?

  • Companies To Watch: Global Blood Therapeutics
    4/1/2022

    Global Blood Therapeutics is intertwining science, business, and social missions to make progress against sickle cell disease.

  • Platforms To Pipelines: Part 1
    4/1/2022

    To discover why companies go about transforming themselves from technology suppliers into biotherapeutics developers, we spoke with the heads of five companies built upon novel platforms for discovery or development of new biotherapeutics, though at various stages and differences in applied strategies.

  • Art Of The Startup — Making New Waves
    3/1/2022

    As Shoreline’s chairman, CEO, and cofounder, Dr. Kleanthis Xanthopoulos draws on his experience of several decades, starting and running companies that aim to overturn prevailing practices in areas of medicine where practice makes imperfect, with treatments that disappoint patients or prove expensive and impractical for many.

  • Companies To Watch: Endevica Bio
    3/1/2022

    Endevica Bio is developing a new treatment for cachexia, a severe wasting disease critical to patients’ survival in cancer and other conditions.

  • Companies To Watch: MiroBio
    2/1/2022

    MiroBio is precisely targeting checkpoint receptors with agonist antibodies for better treatments in autoimmunity.

  • Tackling Uncertainty In Drug R&D
    1/4/2022

    Can bioinformatics help biopharma companies manage their expectations and limit their risk in drug R&D? Ben Zeskind, a CEO who has built and bet his entire career on a positive answer to that question, discusses his reasons for optimism.

  • Companies To Watch: Qlaris Bio
    1/4/2022

    Qlaris Bio is striking at an unaddressed target in the intraocular pressure of glaucoma.

  • Can the FDA & CDC Recover from Recent Politics?
    12/1/2021

    Five leading biopharma executives discuss the perils of political influence over the FDA and CDC and why every member of the industry should care.

  • Long Hauler In The Antibiotics Space
    11/1/2021

    For Ted Schroeder, CEO of Nabriva Therapeutics, the road of his biopharma career led him into the antibiotics space, a mighty steep climb in the biopharma industry.

  • Companies To Watch: Graphite Bio
    11/1/2021

    Graphite Bio focuses on precise repair of genes that cause sickness, starting with Sickle Cell Disease.

  • Going Precommercial — From The Commercial World
    10/1/2021

    Nancy Lurker, a veteran Big-Pharma marketer, now runs a small biopharma. And she admits, “the business models are very, very different.”

  • Companies To Watch: Atea Pharmaceuticals
    10/1/2021

    Atea Pharmaceuticals is creating new nucleotide antivirals, including one the company is jointly developing with Roche to fight COVID-19.

wayne koberstein

Wayne Koberstein


Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.